[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE025294T2 - Új kemokin-kötõ polipeptidek, amelyek képesek gátolni az autoimmunitás, a gyulladás és a rák folyamatát - Google Patents

Új kemokin-kötõ polipeptidek, amelyek képesek gátolni az autoimmunitás, a gyulladás és a rák folyamatát Download PDF

Info

Publication number
HUE025294T2
HUE025294T2 HUE10735337A HUE10735337A HUE025294T2 HU E025294 T2 HUE025294 T2 HU E025294T2 HU E10735337 A HUE10735337 A HU E10735337A HU E10735337 A HUE10735337 A HU E10735337A HU E025294 T2 HUE025294 T2 HU E025294T2
Authority
HU
Hungary
Prior art keywords
pro
ser
polypeptide
leu
thr
Prior art date
Application number
HUE10735337A
Other languages
English (en)
Inventor
Michal Abraham
Orly Eizenberg
Amnon Peled
Original Assignee
Biokine Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokine Therapeutics Ltd filed Critical Biokine Therapeutics Ltd
Publication of HUE025294T2 publication Critical patent/HUE025294T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)

Claims (7)

  1. ÚJ KEMOKIN-KÓTŐ POUPEPTÍDEK, AMELYEK KÉPESEK GÁTOLNI AZ ÁUTOIMMUNITÁS. A GYULLADÁS ÉS A RÁK FOLYAMATÁT SZABADALMI IGÉNYPONTOK 1. tóált polípeptíd. amely tartalmas iegsiább egy kamokibícbemökmej-kotő pepiidet amely egy Fo öoménbez vagy az említett Fc doménnek egy fragmentumához van rögzítve, ahol az említett kemoktn-kőtó pepiidnek olyan aminosav-szekvanciája ven, amely legalább S0% szekvencia-homoíogíát mutat egy amínosav szekvenciához, amely a következők közül választható: ki: SEQ ID NO:1-1S7, és ahol az említett kemoklmkőtő pepid 10-20 aminosav hosszúságú.
  2. 2. Az t. Igénypont szerinti psíípepM amely tartalmaz továbbá egy kapcsaiét (íínkerj. 3. A2, igénypont szerinti poiipepiid, ahol az említett kapcsoló- 4-10 aminosavbél van összeállítva.
  3. 4. Az 1-3. Igénypontok bármelyike szerinti palipepúd, amely tarfeímsz továbbá egy szignál (signaí· pepiidet, 5. A4. igénypont szerinti poiipepiid, amely a kővetkező képlettel bír: W-X--Y-2 ahol a képletben W jelentése egy szignál peptid: X Jelentése az említett ksmokin-kötő pspí-Ö:; Y jelentése az említett kapcsoló; és Z jelentése az említett Fs dómén vagy fragmentuma.
  4. 8. Az' 1. igénypont szerinti: poiipepiid, ahol az említett kemökin-köte pepiid s kővetkezők közöl választható ki; 8KW2 (SEQ IQ NO: 1 ölj ás BKT-P46 (SEQ ID ND:78}, 7. A 4, vagy 5. Igénypont szerinti poiipepiid:. ahol az említett szignál peptid: tartalmaz egy íl-8 szignál: pepiidet, ahot ez oíyan aminossv-szekvenciáva! bír, amely legalább 90% szekvencia hcmclógiát mutat a SEQ ID Nö:T6í-hez. S, Az 1í-7. igénypontok bármelyike szerinti poiipepiid, azzal jellemezve, hogy képessége van gátolni legalább sgy kemakin kötését egy kemokin receptorhoz.
  5. 9, Gyógyászati kompozíció, amely tartalmaz egy, az 1-8. igénypontok bármelyike szerinti pöüpepbdet és egy gyégyászalag elfogadható hordozót.
  6. 18. Az 1-8. igénypontok bármelyike szerinti pólipeptid felhasználásra olyan állapotok kezelésében, amelyek a következők közül választhatók ki: gyulladás, allergia. MsiAtelt tíjfsöSó túlérzékenység (öeiayed type bypersenslvliy), nam-eptimáliS: immunválasz tnob-opiima! immuné respense), rendellenes sejtvándorlás fsbhormal cell mígraiiönj, autoimmun reakció, rheumatoid arthritis,: szisztémás bőfferkas rsystemic topos srymmatosis), szkísrózls muíöptex, beültetés kilökődés Mogrsít rejeotion), cukorba] (diabetesj, vérmérgezés fsspsisj, rák:, rosszindulatú sejtnövekedés (rnaíígnaní cell growth}:, bakteriális fertőzés, vírusos fertőzés, izoieti gyulladás jaribriiis}:, vgsíagfeétgyuiiadás: (edíitls), pikkelysömör (psoriasísj, atherosclerosís, magas vérnyomás, súlyos izömpyengeség (mysslhénia gravlsj és réperfúsiós iszkómiá. ti Izolált poiimíkleodd, amely kódol egy, az l-δ. igénypontok bármelyike szerinti poiípépíidst Í2. A 11, igénypont szerinti izolált poiinukleotid. ahol ez: olyan nukleinssv szekvenciával bír, amely a következők közüt választható ki: SEQ ID NG-:168és. SEQ ID NQ:16S.
  7. 13, Konjuoátum, amely tartalmaz egy, az 1-8. igénypontok bármelyike szerinti poiipeptiöet egy vizoídható polimerhez rögzítve. 14. A13, igénypont szerinti konjugatum, ahol az említett vízoidhafö poilmer poiistíléngiikoi.
HUE10735337A 2009-06-15 2010-06-15 Új kemokin-kötõ polipeptidek, amelyek képesek gátolni az autoimmunitás, a gyulladás és a rák folyamatát HUE025294T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21349309P 2009-06-15 2009-06-15

Publications (1)

Publication Number Publication Date
HUE025294T2 true HUE025294T2 (hu) 2016-02-29

Family

ID=42933139

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10735337A HUE025294T2 (hu) 2009-06-15 2010-06-15 Új kemokin-kötõ polipeptidek, amelyek képesek gátolni az autoimmunitás, a gyulladás és a rák folyamatát

Country Status (11)

Country Link
US (3) US8685398B2 (hu)
EP (1) EP2443137B1 (hu)
JP (1) JP5784010B2 (hu)
KR (1) KR20120046163A (hu)
CN (1) CN102482324B (hu)
BR (1) BRPI1009716A2 (hu)
CA (1) CA2765188A1 (hu)
DK (1) DK2443137T3 (hu)
HU (1) HUE025294T2 (hu)
MX (1) MX2011013457A (hu)
WO (1) WO2010146584A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423007B2 (en) 2002-08-27 2008-09-09 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
EP2942059A1 (en) 2006-12-21 2015-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for use in the treatment of multiple myeloma
MX2011013459A (es) 2009-06-14 2012-05-08 Biokine Therapeutics Ltd Terapia de peptido para incrementar los niveles de plaquetas.
HUE025294T2 (hu) 2009-06-15 2016-02-29 Biokine Therapeutics Ltd Új kemokin-kötõ polipeptidek, amelyek képesek gátolni az autoimmunitás, a gyulladás és a rák folyamatát
WO2012095849A1 (en) 2011-01-10 2012-07-19 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
CN104327158B (zh) * 2014-09-05 2017-02-01 山东省肿瘤防治研究院 大蒜中提取得到的抗肿瘤活性的多肽
US20170226157A1 (en) * 2014-12-09 2017-08-10 Biokine Therapeutics Ltd. Compositions and methods for the treatment of ocular diseases
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
CN108699000B (zh) 2015-12-17 2021-09-21 百欧肯治疗有限公司 用于抑制趋化因子活性及/或癌细胞生长的小分子
WO2017103931A1 (en) 2015-12-17 2017-06-22 Biokine Therapeutics Ltd. Small molecules against cancer
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109310733A (zh) 2016-02-23 2019-02-05 百欧林纳克斯有限公司 治疗急性骨髓性白血病的方法
WO2020030672A1 (en) * 2018-08-10 2020-02-13 Pantherna Therapeutics Gmbh Recombinant nucleic acid construct
KR20200044321A (ko) * 2018-10-19 2020-04-29 아이진 주식회사 염증성 질환의 예방 또는 치료용 약학적 조성물
IL288144B2 (en) 2019-05-15 2024-03-01 Alonbio Ltd Compounds to treat cancer, to inhibit chemokines and/or to kill cells
KR20230046871A (ko) * 2021-09-30 2023-04-06 (주)케어젠 항염증 활성을 갖는 펩타이드 및 이의 용도
KR102609822B1 (ko) * 2021-10-05 2023-12-06 (주)케어젠 항염증 활성을 갖는 펩타이드와 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
UA48104C2 (uk) 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
WO2007052173A2 (en) 2005-02-23 2007-05-10 Endocube S.A.S. Activity of thap-family chemokine-binding domains
WO2007094005A2 (en) * 2006-02-17 2007-08-23 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases
HUE025294T2 (hu) 2009-06-15 2016-02-29 Biokine Therapeutics Ltd Új kemokin-kötõ polipeptidek, amelyek képesek gátolni az autoimmunitás, a gyulladás és a rák folyamatát

Also Published As

Publication number Publication date
WO2010146584A1 (en) 2010-12-23
US8685398B2 (en) 2014-04-01
US20120087921A1 (en) 2012-04-12
US20170015708A1 (en) 2017-01-19
DK2443137T3 (en) 2015-08-24
CN102482324A (zh) 2012-05-30
US20140154249A1 (en) 2014-06-05
EP2443137A1 (en) 2012-04-25
JP5784010B2 (ja) 2015-09-24
CN102482324B (zh) 2014-07-02
KR20120046163A (ko) 2012-05-09
EP2443137B1 (en) 2015-05-20
BRPI1009716A2 (pt) 2016-10-11
US9493557B2 (en) 2016-11-15
CA2765188A1 (en) 2010-12-23
MX2011013457A (es) 2012-05-08
JP2012529906A (ja) 2012-11-29

Similar Documents

Publication Publication Date Title
DK2443137T3 (en) NOVEL chemokine-binding peptides capable of impeding the sequence for immunity, inflammation and cancer
US11060097B2 (en) Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins
RU2733496C2 (ru) Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний
WO2014164680A1 (en) Cd20-binding immunotoxins for inducing cellular internalization and methods using same
JP2008531608A (ja) Ｙｋｌ−４０モノクローナル抗体
US7825085B2 (en) Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells
KR20220050166A (ko) Igm 글리코변이체
KR102263643B1 (ko) 면역 관련 질환의 예방 또는 치료용 조성물
RU2694412C2 (ru) Моноклональные антитела и способы их применения
JP2023055875A (ja) Ｈｉｖ融合体を標的とするポリペプチド
CN110885377B (zh) 抗cd47/vegf双特异性抗体及其应用
TW202033557A (zh) 特異性結合至人類Ｔ細胞受體之ＴＲＢＶ－９家族之β區的單株抗體及其使用之方法
WO2022050401A2 (en) Interleukin-2 muteins and uses thereof
KR101570453B1 (ko) 돼지 유행성 설사 바이러스의 재조합 스파이크 1 단백질을 발현하는 재조합 세포
CN114990129B (zh) 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
TW202039574A (zh) 針對人類ＴＣＲ ＴＲＢＶ９第９家族之β鏈區的人類化抗體及其使用方法
JP2003507011A (ja) Ｉｌ−１６拮抗剤
WO2023169524A1 (zh) 白细胞介素2突变体以及含有其的复合物
CN111320691A (zh) 一种抗人4-1bb单克隆抗体及其应用
HUE026977T2 (hu) Promiszkuus HER-2/NEU CD4 T-sejt epitópok
CN114401985A (zh) 用于治疗免疫复合物介导的肾病症的重组IgG Fc多聚体
KR20220033963A (ko) 코로나바이러스 유래 수용체 결합 도메인 및 뉴클레오캡시드 단백질을 포함하는 융합단백질 및 이의 용도